表紙
市場調查報告書

兒童用醫藥品的全球市場:2020年∼2024年

Global Pediatric Medicines Market 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 538559
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
兒童用醫藥品的全球市場:2020年∼2024年 Global Pediatric Medicines Market 2020-2024
出版日期: 2020年03月24日內容資訊: 英文 120 Pages
簡介

全球兒童用醫藥品市場在2020年∼2024年的預測期間內,預計將以5%的年複合成長率增長,達到277億1,000萬美元的規模。市場主要的成長要素有處方藥的開發,小兒科人群的增多以及環境的迅速惡化導致過敏症狀等。

本報告提供全球兒童用醫藥品市場相關調查分析,提供市場規模及成長率,市場趨勢,推動市場要素,課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 2019年的市場規模
  • 市場預測:從2019年到2024年的預測

波特的五力分析

各給藥途徑市場區隔

  • 市場區隔
  • 各類型比較:市場規模與預測2019-2024
  • 腸溶性
  • 非口服
  • 局部
  • 各給藥途徑市場機會

客戶形勢

  • 概要

各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模與預測2019-2024
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 地區的市場機會

成長要素,課題,及趨勢

  • 市場成長要素
  • 交易量的成長要素-需求主導型成長
  • 交易量的成長要素-供給主導型成長
  • 交易量的成長要素-外部要素
  • 交易量的成長要素-需求轉移到鄰近市場
  • 價格上升要素-通貨膨脹
  • 價格成長要素-從低價格單位轉變到高價格單位

業者情勢

  • 概要
  • 形勢的創新

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • AbbVie Inc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • 武田藥品工業

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR43146

Technavio has been monitoring the pediatric medicines market and it is poised to grow by $ 27.71 bn during 2020-2024 progressing at a CAGR of 5% during the forecast period. Our reports on pediatric medicines market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven formulatory advancement, high pediatric population, and rapid environmental deterioration resulting in several allergic conditions. In addition, formulatory advancement is anticipated to boost the growth of the market as well.

The pediatric medicines market analysis include type segments and geographic segments.

Technavio's ‘pediatric medicines market ’ is segmented as below:

By Type:

  • Respiratory diseases
  • Infectious diseases
  • Gastrointestinal diseases
  • CNS diseases
  • Oncological diseases
  • Others

By Geographic Landscape:

  • Asia
  • Europe
  • North America
  • ROW

This study identifies inorganic growth strategies as one of the prime reasons driving the pediatric medicines market growth during the next few years. Government initiatives, and oral soluble films will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our pediatric medicines market covers the following areas:

  • Pediatric Medicines Market sizing
  • Pediatric Medicines Market forecast
  • Pediatric Medicines Market industry analysis

Technavio's ‘robust vendor analysis ’ is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading pediatric medicines market vendors that include AbbVie Inc., Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, and Takeda Pharmaceutical Co. Ltd.. Also, the pediatric medicines market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Other 1

  • Market segments
  • Comparison by Other1
  • Enteral - Market size and forecast 2019-2024
  • Parenteral - Market size and forecast 2019-2024
  • Topical - Market size and forecast 2019-2024
  • Market opportunity by Other1

Customer landscape

  • Overview

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography

Drivers, Challenges, and Trends

  • Market drivers
  • Volume driver - Demand led growth
  • Volume driver - Supply led growth
  • Volume driver - External factors
  • Volume driver - Demand shift in adjacent markets
  • Price driver - Inflation
  • Price driver - Shift from lower to higher priced units
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • AbbVie Inc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibits

  • 1.Key Finding 1
  • 2.Key Finding 2
  • 3.Key Finding 3
  • 4.Key Finding 5
  • 5.Key Finding 6
  • 6.Key Finding 7
  • 7.Key Finding 8
  • 8.Parent market
  • 9.Market characteristics
  • 10.Offerings of vendors included in the market definition
  • 11.Market segments
  • 12.Global - Market size and forecast 2019 - 2024 ($ billion)
  • 13.Global market: Year-over-year growth 2019 - 2024 (%)
  • 14.Five forces analysis 2019 & 2024
  • 15.Bargaining power of buyers
  • 16.Bargaining power of suppliers
  • 17.Threat of new entrants
  • 18.Threat of substitutes
  • 19.Threat of rivalry
  • 20.Market condition - Five forces 2019
  • 21.Other1 - Market share 2019-2024 (%)
  • 22.Comparison by Other1
  • 23.Enteral - Market size and forecast 2019-2024 ($ billion)
  • 24.Enteral - Year-over-year growth 2019-2024 (%)
  • 25.Parenteral - Market size and forecast 2019-2024 ($ billion)
  • 26.Parenteral - Year-over-year growth 2019-2024 (%)
  • 27.Topical - Market size and forecast 2019-2024 ($ billion)
  • 28.Topical - Year-over-year growth 2019-2024 (%)
  • 29. Market opportunity by Other1
  • 30.Customer landscape
  • 31.Market share by geography 2019-2024 (%)
  • 32.Geographic comparison
  • 33.North America - Market size and forecast 2019-2024 ($ billion)
  • 34.North America - Year-over-year growth 2019-2024 (%)
  • 35.Europe - Market size and forecast 2019-2024 ($ billion)
  • 36.Europe - Year-over-year growth 2019-2024 (%)
  • 37.Asia - Market size and forecast 2019-2024 ($ billion)
  • 38.Asia - Year-over-year growth 2019-2024 (%)
  • 39.ROW - Market size and forecast 2019-2024 ($ billion)
  • 40.ROW - Year-over-year growth 2019-2024 (%)
  • 41.Key leading countries
  • 42.Market opportunity by geography ($ billion)
  • 43.Impact of drivers and challenges
  • 44.Vendor landscape
  • 45.Landscape disruption
  • 46.Industry risks
  • 47.Vendors covered
  • 48.Market positioning of vendors
  • 49.AbbVie Inc. - Overview
  • 50.AbbVie Inc. - Business segments
  • 51.AbbVie Inc. - Key offerings
  • 52.AbbVie Inc. - Key customers
  • 53.AbbVie Inc. - Segment focus
  • 54.Bayer AG - Overview
  • 55.Bayer AG - Business segments
  • 56.Bayer AG - Key offerings
  • 57.Bayer AG - Key customers
  • 58.Bayer AG - Segment focus
  • 59.F. Hoffmann-La Roche Ltd. - Overview
  • 60.F. Hoffmann-La Roche Ltd. - Business segments
  • 61.F. Hoffmann-La Roche Ltd. - Key offerings
  • 62.F. Hoffmann-La Roche Ltd. - Key customers
  • 63.F. Hoffmann-La Roche Ltd. - Segment focus
  • 64.GlaxoSmithKline Plc - Overview
  • 65.GlaxoSmithKline Plc - Business segments
  • 66.GlaxoSmithKline Plc - Key offerings
  • 67.GlaxoSmithKline Plc - Key customers
  • 68.GlaxoSmithKline Plc - Segment focus
  • 69.Johnson & Johnson - Overview
  • 70.Johnson & Johnson - Business segments
  • 71.Johnson & Johnson - Key offerings
  • 72.Johnson & Johnson - Key customers
  • 73.Johnson & Johnson - Segment focus
  • 74.Merck & Co. Inc. - Overview
  • 75.Merck & Co. Inc. - Product and service
  • 76.Merck & Co. Inc. - Key offerings
  • 77.Merck & Co. Inc. - Key customers
  • 78.Merck & Co. Inc. - Segment focus
  • 79.Novartis AG - Overview
  • 80.Novartis AG - Business segments
  • 81.Novartis AG - Key offerings
  • 82.Novartis AG - Key customers
  • 83.Novartis AG - Segment focus
  • 84.Pfizer Inc. - Overview
  • 85.Pfizer Inc. - Business segments
  • 86.Pfizer Inc. - Key offerings
  • 87.Pfizer Inc. - Key customers
  • 88.Pfizer Inc. - Segment focus
  • 89.Sanofi - Overview
  • 90.Sanofi - Business segments
  • 91.Sanofi - Key offerings
  • 92.Sanofi - Key customers
  • 93.Sanofi - Segment focus
  • 94.Takeda Pharmaceutical Co. Ltd. - Overview
  • 95.Takeda Pharmaceutical Co. Ltd. - Product and service
  • 96.Takeda Pharmaceutical Co. Ltd. - Key offerings
  • 97.Takeda Pharmaceutical Co. Ltd. - Key customers
  • 98.Takeda Pharmaceutical Co. Ltd. - Segment focus
  • 99.Currency conversion rates for US$
  • 100.Research Methodology
  • 101.Validation techniques employed for market sizing
  • 102Information sources
  • 103.List of abbreviations